Exhibit 99.1
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com |
August 28, 2020
Corporate Relationship Department | National Stock Exchange of India Ltd. |
BSE Limited | “Exchange Plaza” |
Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
Mumbai – 400 001 | Mumbai – 400 051 |
Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
22722037 / 22722039 | 26598238 |
Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Dear Sirs,
Sub: Intimation
Further to our press release dated November 6, 2015 with regard to the receipt of Warning Letter from US FDA for three of our sites (API manufacturing facilities at Srikakulum, Andhra Pradesh and Miryalguda, Telengana, and Oncology formulation manufacturing facility at Duvadda, Visakhapatnam, Andhra Pradesh); we have now been informed by US FDA that based on its evaluation, we have addressed the violations and deviations contained in the said Warning Letter.
With this the said Warning Letter has been closed.
This is for your information.
With regards,
/s/ Sandeep Poddar | ||
Sandeep Poddar |
Company Secretary
CC:- New York Stock Exchange Inc.(Stock Code :RDY)